Steris (STE) has disclosed a new risk, in the Corporate Activity and Growth category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Steris faces a modest governance and perception risk stemming from insider share sale arrangements disclosed under Item 5. Other Information. While no broad pattern of new or modified trading plans emerged in the quarter, the adoption of a Rule 10b5-1 Trading Plan by Senior Vice President and General Counsel J. Adam Zangerle for the sale of up to 16,003 ordinary shares may draw investor scrutiny. Although such plans are designed to provide an affirmative defense against insider trading allegations, their existence can still raise questions about insiders’ expectations of future share performance. The eventual volume of sales tied to unvested awards and tax withholding at vesting may influence market sentiment depending on the timing and visibility of these transactions.
The average STE stock price target is $295.50, implying 17.19% upside potential.
To learn more about Steris’ risk factors, click here.